Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$7.19 USD
+0.21 (3.01%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $7.05 -0.14 (-1.95%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
COYA 7.19 +0.21(3.01%)
Will COYA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COYA
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
Other News for COYA
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
7 Biotech Stocks to Put on Your Breakthrough Radar
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease